Informations générales (source: ClinicalTrials.gov)
(POMEGA)
Interventional
Phase 3
University Hospital, Strasbourg, France (Voir sur ClinicalTrials)
mai 2015
février 2018
29 juin 2024
Determining whether treatment with an optimized formulation of omega 3 for 6 weeks causes
a 40% decrease in the average concentration of total microparticles (MPs) in the
atheromatous plaque.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Nouvel Hopital Civil - 67091 - Strasbourg - France | Yannick GEORG, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Men or women between 30 and 85 years
- Affiliated to a social security scheme
- Informed consent signed
- Patients to get an endarterectomy carotid stenosis> 70% asymptomatic is
- Women of childbearing potential (negative pregnancy test), effective contraception
for the duration of the study
- Men or women between 30 and 85 years
- Affiliated to a social security scheme
- Informed consent signed
- Patients to get an endarterectomy carotid stenosis> 70% asymptomatic is
- Women of childbearing potential (negative pregnancy test), effective contraception
for the duration of the study
- Inability to give informed information about the study (subject in emergencies,
difficulty of understanding ...)
- Patient treated by OMACOR®
- Patients on oral anticoagulant (AVK, apixaban, dabigatran, rivaroxaban)
- Daily consumption of fish oil (medical food with fish oil (omega 3))
- Carotid Restenosis
- Pregnancy (positive pregnancy test) and lactation
- Hypersensitivity to fish
- Allergy to fish
- Subject under judicial protection
- Subjects under guardianship or curatorship